Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Moffitt Consortium Study Answers Questions About Long-Term Survivorship Following CAR T Treatment

Axicabtagene ciloleucel, commonly known as axi-cel, is an innovative immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.

August 5, 2024


September 10 2024

September 9 2024

September 8 2024

September 7 2024

September 6 2024

September 5 2024

September 4 2024

September 3 2024

September 2 2024

September 1 2024

August 31 2024

August 30 2024

August 29 2024

August 28 2024